The researchers reviewed medical records from 180 adult patients who underwent single-level PLDFs and calculated costs for allogeneic blood transfusion, setting up the cell saver recovery system and infusing autologous blood from cell saver. Averted blood transfusions and quality-adjusted life years marked effectiveness.
Transfusion rate decreased from 40 to 38.7 percent with the cell saver approach, with a cost effectiveness ratio of $55,538 per allogeneic transfusion averted. The cell saver approach was not cost effective with a ratio of $5.6 million per quality-adjusted life years, above the cost-effective threshold of $100,000 per life year.
More Articles on Spine:
Dr. Hussein Alahmadi Joins The Hospital of Central Connecticut
5 Factors for Spine Surgeons to Negotiate Better Payor Contracts
7 Trends Impacting the Future of Spinal Surgery
